富马酸水合酶缺陷型肾细胞癌 (FHRCC) 是一种罕见且具有侵袭性的肾细胞癌。 68Ga-FAPI PET/CT 对 FHRCC 的诊断价值仍有待探索。因此，我们比较了 68Ga-FAPI-04 和 18F-FDG PET/CT 在 FHRCC 中的潜在价值。FHRCC 患者于 2022 年 5 月至 2023 年 12 月接受了 68Ga-FAPI-04 和 18F-FDG PET/CT。使用 Wilcoxon 符号秩检验比较两种示踪剂的肝脏比率 (TLR)。 纳入了 11 名具有 83 个病变的患者。 18F-FDG PET/CT检出病灶率高于68Ga-FAPI-04 PET/CT：原发肿瘤：75.0%（6/8）比50.0%（4/8）；淋巴结：94.9% (37/39) 对比 89.7% (35/39)；和骨病变：100.0% (21/21) 对比 90.5% (19/21)。在半定量分析中，18F-FDG PET/CT 上原发灶和转移灶的中位 SUVmax 与 68Ga-FAPI-04 PET/CT 相当（原发灶：13.86 vs 16.35，P = 1.000；淋巴结：10.04 vs 9.33，P = 0.517；骨病变：13.49 vs 9.84，P = 0.107；内脏病变：8.54 vs 4.20，P = 0.056）。然而，68Ga-FAPI-04 PET/CT 上原发灶和转移灶的中位 TLR 高于 18F-FDG PET/CT（原发灶：30.44 vs 5.41，P = 0.010；淋巴结：17.71 vs 3.95，P 18F-FDG PET/CT 比 68Ga-FAPI-04 PET/CT 检测到更多原发性和转移性 FHRCC 病变。然而，68Ga-FAPI-04 PET/CT 上的 FHRCC 较高的 TLR 可能表明针对 FHRCC 中成纤维细胞激活蛋白的治疗潜力。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

Fumarate hydratase-deficient renal cell cancer (FHRCC) is a rare and aggressive form of renal cell carcinoma. The diagnostic value of 68Ga-FAPI PET/CT for FHRCC remains unexplored. Therefore, we compared the potential value of 68Ga-FAPI-04 and 18F-FDG PET/CT in FHRCC.Patients with FHRCC underwent 68Ga-FAPI-04 and 18F-FDG PET/CT from May 2022 to December 2023. The SUVmax and tumor-to-liver ratio (TLR) of both tracers were compared using the Wilcoxon signed rank test.Eleven patients with 83 lesions were enrolled. The rate of 18F-FDG PET/CT in detecting lesions was higher than that of 68Ga-FAPI-04 PET/CT: primary tumors: 75.0% (6/8) versus 50.0% (4/8); lymph nodes: 94.9% (37/39) versus 89.7% (35/39); and bone lesions: 100.0% (21/21) versus 90.5% (19/21). The median SUVmax of primary and metastatic lesions on 18F-FDG PET/CT was comparable to 68Ga-FAPI-04 PET/CT in semiquantitative analysis (primary lesions: 13.86 vs 16.35, P = 1.000; lymph nodes: 10.04 vs 9.33, P = 0.517; bone lesions: 13.49 vs 9.84, P = 0.107; visceral lesions: 8.54 vs 4.20, P = 0.056). However, the median TLRs of primary and metastatic lesions on 68Ga-FAPI-04 PET/CT were higher than that of 18F-FDG PET/CT (primary lesions: 30.44 vs 5.41, P = 0.010; lymph nodes: 17.71 vs 3.95, P = 0.000; bone lesions: 15.94 vs 5.21, P = 0.000; visceral lesions: 9.26 vs 3.44, P = 0.003).18F-FDG PET/CT detected more primary and metastatic FHRCC lesions than 68Ga-FAPI-04 PET/CT. However, the higher TLR in FHRCC on 68Ga-FAPI-04 PET/CT may indicate therapeutic potential in targeting fibroblast activation protein in FHRCC.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.